92 related articles for article (PubMed ID: 9581910)
1. Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into athymic rodents.
Brauker J; Frost GH; Dwarki V; Nijjar T; Chin R; Carr-Brendel V; Jasunas C; Hodgett D; Stone W; Cohen LK; Johnson RC
Hum Gene Ther; 1998 Apr; 9(6):879-88. PubMed ID: 9581910
[TBL] [Abstract][Full Text] [Related]
2. Expression of human factor IX cDNA in mice by implants of genetically modified skin fibroblasts from a hemophilia B patient.
Zhou JM; Dai YF; Qiu XF; Hou GY; Akira Y; Xue JL
Sci China B; 1993 Sep; 36(9):1082-92. PubMed ID: 8274202
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast transplantation in rats: transduction and function of foreign genes.
Neuzil D; Holzman M; Rozga J; Levine J; Moscioni AD; Demetriou AA
J Surg Res; 1993 Jun; 54(6):631-7. PubMed ID: 8412074
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo fibroblast transduction in rabbits results in long-term (>600 days) factor IX expression in a small percentage of animals.
Chen L; Nelson DM; Zheng Z; Morgan RA
Hum Gene Ther; 1998 Nov; 9(16):2341-51. PubMed ID: 9829533
[TBL] [Abstract][Full Text] [Related]
5. Persistent delivery of factor IX in mice: gene therapy for hemophilia using implantable microcapsules.
Hortelano G; Xu N; Vandenberg A; Solera J; Chang PL; Ofosu FA
Hum Gene Ther; 1999 May; 10(8):1281-8. PubMed ID: 10365659
[TBL] [Abstract][Full Text] [Related]
6. Long-term expression of human factor IX cDNA in rabbits.
Zhou JM; Qiu XF; Lu DR; Lu JY; Xue JL
Sci China B; 1993 Nov; 36(11):1333-41. PubMed ID: 8142022
[TBL] [Abstract][Full Text] [Related]
7. Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B.
Hortelano G; Al-Hendy A; Ofosu FA; Chang PL
Blood; 1996 Jun; 87(12):5095-103. PubMed ID: 8652822
[TBL] [Abstract][Full Text] [Related]
8. Long-term expression of human clotting factor IX from retrovirally transduced primary human keratinocytes in vivo.
White SJ; Page SM; Margaritis P; Brownlee GG
Hum Gene Ther; 1998 May; 9(8):1187-95. PubMed ID: 9625258
[TBL] [Abstract][Full Text] [Related]
9. Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells.
Hurwitz DR; Kirchgesser M; Merrill W; Galanopoulos T; McGrath CA; Emami S; Hansen M; Cherington V; Appel JM; Bizinkauskas CB; Brackmann HH; Levine PH; Greenberger JS
Hum Gene Ther; 1997 Jan; 8(2):137-56. PubMed ID: 9017418
[TBL] [Abstract][Full Text] [Related]
10. Stage I clinical trial of gene therapy for hemophilia B.
Lu DR; Zhou JM; Zheng B; Qiu XF; Xue JL; Wang JM; Meng PL; Han FL; Ming BH; Wang XP
Sci China B; 1993 Nov; 36(11):1342-51. PubMed ID: 8142023
[TBL] [Abstract][Full Text] [Related]
11. In vivo delivery of recombinant human growth hormone from genetically engineered human fibroblasts implanted within Baxter immunoisolation devices.
Josephs SF; Loudovaris T; Dixit A; Young SK; Johnson RC
J Mol Med (Berl); 1999 Jan; 77(1):211-4. PubMed ID: 9930965
[TBL] [Abstract][Full Text] [Related]
12. Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice.
Yao SN; Smith KJ; Kurachi K
Gene Ther; 1994 Mar; 1(2):99-107. PubMed ID: 7584074
[TBL] [Abstract][Full Text] [Related]
13. High efficient transfer and expression of human clotting factor IX cDNA in cultured human primary skin fibroblasts from hemophilia B patient by retroviral vectors.
Dai YF; Qiu XF; Xue JL; Liu ZD
Sci China B; 1992 Feb; 35(2):183-93. PubMed ID: 1581003
[TBL] [Abstract][Full Text] [Related]
14. Comparison of retroviral and adeno-associated viral vectors designed to express human clotting factor IX.
Chen L; Perlick H; Morgan RA
Hum Gene Ther; 1997 Jan; 8(2):125-35. PubMed ID: 9017417
[TBL] [Abstract][Full Text] [Related]
15. Production of minigene-containing retroviral vectors using an alphavirus/retrovirus hybrid vector system.
Wahlfors JJ; Morgan RA
Hum Gene Ther; 1999 May; 10(7):1197-206. PubMed ID: 10340551
[TBL] [Abstract][Full Text] [Related]
16. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host.
Poller W; Schneider-Rasp S; Liebert U; Merklein F; Thalheimer P; Haack A; Schwaab R; Schmitt C; Brackmann HH
Gene Ther; 1996 Jun; 3(6):521-30. PubMed ID: 8789802
[TBL] [Abstract][Full Text] [Related]
17. Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B.
Palmer TD; Thompson AR; Miller AD
Blood; 1989 Feb; 73(2):438-45. PubMed ID: 2917183
[TBL] [Abstract][Full Text] [Related]
18. Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis.
Hortelano G; Wang L; Xu N; Ofosu FA
Haemophilia; 2001 Mar; 7(2):207-14. PubMed ID: 11260281
[TBL] [Abstract][Full Text] [Related]
19. Survival of macroencapsulated allogeneic parathyroid tissue one year after transplantation in nonimmunosuppressed humans.
Tibell A; Rafael E; Wennberg L; Nordenström J; Bergström M; Geller RL; Loudovaris T; Johnson RC; Brauker JH; Neuenfeldt S; Wernerson A
Cell Transplant; 2001; 10(7):591-9. PubMed ID: 11714193
[TBL] [Abstract][Full Text] [Related]
20. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients.
Qiu X; Lu D; Zhou J; Wang J; Yang J; Meng P; Hsueh JL
Chin Med J (Engl); 1996 Nov; 109(11):832-9. PubMed ID: 9275366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
